News
Press releases, publications and events.
Company announcements, the research JuvNET was built on, and Juvena's posters, presentations and corporate overview.
Press releases
Company announcements
August 2026
Juvena Therapeutics Appoints Julie Anne Smith as Chief Executive Officer
Read releaseJanuary 2026
Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline
Read releaseJune 2025
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Read releaseMay 2025
Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
Read releaseJanuary 2024
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
Read releaseJanuary 2023
Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development
Read releaseNovember 2022
Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Read releaseFebruary 2022
Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1
Read releaseNo press releases in that year.
Publications
The research behind JuvNET
The founding papers on the stem-cell secretome, a selection of Juvena's posters and presentations, and selected literature on secreted proteins.
Founding research
- Mechanisms of action of hESC-secreted proteins that enhance human and mouse myogenesis
- hESC-secreted proteins can be enriched for multiple regenerative therapies by heparin-binding
- Embryonic anti-aging niche
Selected posters and presentations
- Poster: JUV-161, an investigational fusion protein, in a mouse model of type 2 diabetes (ENDO 2025). (PDF)
- Presentation at the Endocrine Society annual meeting: Jeremy O'Connell, Priya Handa and Ritwik Datta (image)
- Poster: preclinical development of JUV-161 for myotonic dystrophy type 1 (PDF)
- Poster: secreted proteins from pluripotent stem cells and the function of lung alveolar cells under fibrotic stress (IPF Summit 2023). (PDF)
- Poster: an ML-enhanced platform that uses stem-cell secretomes to identify therapeutic proteins (5th Age-Related Disease Therapeutics Summit 2023). (PDF)
- Panel presentation by Jeremy O'Connell (PDF)
Selected literature on stem-cell secreted proteins
- Autologous treatment for ALS with implication for broad neuroprotection
- Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
- Emergence of the stem cell secretome in regenerative engineering
- Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases
- Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential
- Mesenchymal stem cells: time to change the name!
- Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth
Events and presentations
The corporate overview, always current.
Juvena's corporate overview and presentation materials are posted on one page and replaced whenever a new version is issued.
Events and presentationsMedia contact
For press and investor inquiries
Bek Madjidov · media@juvenatherapeutics.com
General inquiries · info@juvenatherapeutics.com